

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of

1

NOV 02 2001

Complete if Known

Application Number 09/845,717

Filing Date May 02, 2001

First Named Inventor Soeren Nielsen

Group Art Unit 1647

Examiner Name DEBERRY

Attorney Docket Number NIELSEN=3B

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|-----------------------|--------------------------|--|----------------|
| AM | AA | FRANKLIN, H. et al. Erythropoietin: A Model System For Studying Oxygen-Dependent Gene Regulation, The Journal of Experimental Biology 201, 1197-1201 (24 March 1998) | |
| | AB | ANNA CATANIA et al., The Neuropeptide α -MSH Has Specific Receptors On Neutrophils and Reduces Chemotaxis In Vitro Peptides Vol. 17 No. 4PP. 675-679, 1996 | |
| | AC | JOACHIM FANDREY, et al. Cobalt Chloride and Desferrioxamine Antagonize the Inhibition of Erythropoietin Production by Reactive Oxygen Species Kidney International, Vol. 51 (1997) PP. 492-496 | |
| | AD | KWON, TAE-HWAN, et al., Reduced Abundance of Aquaporins in Rats With Bilateral Ischemia-Induced Acute Renal Failure: Prevention By α -MSH, Am.J.Physiol, 277:F413-F427, 1999 | |
| | AE | JAMES M. LIPTON AND ANNA CATANIA, Anti-Inflammatory Actions Of The Neuroimmunomodulator α -MSH, Immunology Today, 18:(3)=140 -145 March (1997) | |
| | AF | NILUM RAJORA, et al, α -MSH Modulates Local and Circulating Tumor Necrosis Factory- α in Experimental Brain Inflammation, Journal of Neuroscience, March 15, 1997 17(6):2181-2186 | |
| | AG | NILUM RAJORA, et al. α -MSH Modulates Experimental Inflammatory Bowel Disease, Peptides, Vol. 3, pp. 381-385, 1997 | |
| | AH | PETER J. RATCLIFFE, et al., Oxygen Regulated Gene Expression: Erythropoietin as a Model System, Kidney International, Vol. 51 (1997), pp. 514-526 | |
| | AI | YASUTAKA SADAMOT, et al. Erythropoietin Prevents Place Navigation Disability and Cortical Infarction in Rats with Permanent Occlusion of the Middle Cerebral Artery, Biochemical and Biophysical Research Communications 253, 26-32 (1998) | |
| | AJ | MASAHIRO SAKANAKA, et al. IN Vivo Evidence That Erythropoietin Protects Neurons From Ischemic Damage, Proc. Natl. Acad. Sci. USA Vol. 95, pp. 4635-4640, April 1998 | |
| | AK | FRANCESCO SQUADRITO, et al. Adrenocorticotropin Reverses Vascular Dysfunction and Protects Against Splanchnic Artery Occlusion Shock, British Journal of Pharmacology (1999), 128, 816-822 | |
| | AL | FRANCESCO SQUADRITO, et al., Recombinant Human Erythropoietin Inhibits iNOS Activity and Reverts Vascular Dysfunction in Splanchnic Artery Occlusion Shock, British Journal of Pharmacology (1999), 127, 482-488 | |
| AM | AM | ROBERT A. STAR, et al., Evidence of Autocrine Modulation of Macrophage Nitric oxide Synthase by α -Melanocyte-Stimulation, Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 8016-8020, August 1995 | |

Examiner
Signature

Regre M. Noel By

Date
Considered

3/9/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

[illegible]

